Nuvalent | IPO Presentation Deck | 40 slides · page 12 of 40
The table highlights the clinical limitations of current standard-of-care drugs (Crizotinib, Entrectinib) due to resistance mutations like G2032R and CNS involvement.
Pitch deck · market_sizing · size_opportunity · balanced density
Slide locked Sign in to view
Slide schematic 4/4
source-note 1/1 table 1/1 title 2/2
Components 4
source-note data action-title headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1